Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9

Goldstein, 2015, A century of cholesterol and coronaries: from plaques to genes to statins, Cell, 161, 161, 10.1016/j.cell.2015.01.036

DuBroff, 2017, Cholesterol paradox: a correlate does not a surrogate make, Evid Based Med, 22, 15, 10.1136/ebmed-2016-110602

Ravnskov, 2016, Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review, BMJ Open, 6, e010401., 10.1136/bmjopen-2015-010401

Camejo, 1975, The participation of aortic proteins in the formation of complexes between low density lipoproteins and intima-media extracts, Atherosclerosis, 21, 77, 10.1016/0021-9150(75)90095-7

Skålén, 2002, Subendothelial retention of atherogenic lipoproteins in early atherosclerosis, Nature, 417, 750, 10.1038/nature00804

Schwenke, 1989, Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries, Arteriosclerosis, 9, 908, 10.1161/01.ATV.9.6.908

Frank, 1989, Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching, J Lipid Res, 30, 967, 10.1016/S0022-2275(20)38299-7

Tabas, 2007, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, Circulation, 116, 1832, 10.1161/CIRCULATIONAHA.106.676890

Nordestgaard, 1988, Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits, J Lipid Res, 29, 1491, 10.1016/S0022-2275(20)38428-5

Descamps, 2004, Lipoprotein concentrations in newborns are associated with allelic variations in their mothers, Atherosclerosis, 172, 287, 10.1016/j.atherosclerosis.2003.11.002

Chapman, 1980, Animal lipoproteins: chemistry, structure, and comparative aspects, J Lipid Res, 21, 789, 10.1016/S0022-2275(20)34780-5

Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society, Eur Heart J, 34, 3478, 10.1093/eurheartj/eht273

Cuchel, 2014, Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, Eur Heart J, 35, 2146, 10.1093/eurheartj/ehu274

Khera, 2016, Diagnostic yield of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia, J Am Coll Cardiol, 67, 2578, 10.1016/j.jacc.2016.03.520

Benn, 2016, Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217, Eur Heart J, 37, 1384, 10.1093/eurheartj/ehw028

Raal, 1999, Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia, Am J Cardiol, 83, 1330, 10.1016/S0002-9149(99)00095-8

Schmidt, 1996, Relationship of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia, Am J Cardiol, 77, 575, 10.1016/S0002-9149(97)89309-5

Wiegman, 2015, Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment, Eur Heart J, 36, 2425, 10.1093/eurheartj/ehv157

Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, 354, 1264, 10.1056/NEJMoa054013

Emerging Risk Factors, 2012, Lipid-related markers and cardiovascular disease prediction, JAMA, 307, 2499

Prospective Studies Collaboration, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4

Lawlor, 2008, Mendelian randomization: using genes as instruments for making causal inferences in epidemiology, Stat Med, 27, 1133, 10.1002/sim.3034

Teslovich, 2010, Biological, clinical and population relevance of 95 loci for blood lipids, Nature, 466, 707, 10.1038/nature09270

Global Lipids Genetics Consortium, 2013, Discovery and refinement of loci associated with lipid levels, Nat Genet, 45, 1274, 10.1038/ng.2797

Ference, 2015, Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps, Curr Opin Lipidol, 26, 566, 10.1097/MOL.0000000000000247

CARDIoGRAMplusC4D Consortium, 2015, A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease, Nat Genet, 47, 1121, 10.1038/ng.3396

Ference, 2012, Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis, J Am Coll Cardiol, 60, 2631, 10.1016/j.jacc.2012.09.017

Linsel-Nitschke, 2008, Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease: a Mendelian Randomisation study, PLoS One, 3, e2986., 10.1371/journal.pone.0002986

Holmes, 2015, Mendelian randomization of blood lipids for coronary heart disease, Eur Heart J, 36, 539, 10.1093/eurheartj/eht571

Ference, 2015, Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study, J Am Coll Cardiol, 65, 1552, 10.1016/j.jacc.2015.02.020

Cholesterol Treatment Trialists’ (CTT) Collaboration, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5

Collins, 2016, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, 388, 2532, 10.1016/S0140-6736(16)31357-5

Boekholdt, 2012, Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis, JAMA, 307, 1302, 10.1001/jama.2012.366

Nissen, 2006, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial, JAMA, 295, 1556, 10.1001/jama.295.13.jpc60002

Nicholls, 2011, Effect of two intensive statin regimens on progression of coronary disease, N Engl J Med, 365, 2078, 10.1056/NEJMoa1110874

Garcia-Calvo, 2005, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1), Proc Natl Acad Sci USA, 102, 8132, 10.1073/pnas.0500269102

Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489

Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3

Lauridsen, 2015, Genetic variation in the cholesterol transporter NPC1L1, ischemic vascular disease and gallstone disease, Eur Heart J, 36, 1601, 10.1093/eurheartj/ehv108

Sabatine, 2016, Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) Trial, Am Heart J, 173, 94, 10.1016/j.ahj.2015.11.015

Ference, 2016, Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes, N Engl J Med, 375, 2144, 10.1056/NEJMoa1604304

Nicholls, 2016, Effect of evolocumab on progression of coronary disease in statin-treated patients. The GLAGOV randomized clinical trial, . JAMA, 316, 2373, 10.1001/jama.2016.16951

Lipid Research Clinics Program, 1984, The Lipid Research Clinics coronary primary prevention trial results: reduction in the incidence of coronary artery disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025

Buchwald, 1990, Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH), N Engl J Med, 323, 946, 10.1056/NEJM199010043231404

Silverman, 2016, Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis, JAMA, 316, 1289, 10.1001/jama.2016.13985

Lincoff AM for the ACCELERATE Trial Investigators

Hill, 1965, The environment and disease. Association or causation?, Proc R Soc Med, 58, 295

Ford, 2016, Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study, Circulation, 133, 1073, 10.1161/CIRCULATIONAHA.115.019014

Catapano, 2016, 2016 ESC/EAS guidelines for the management of dyslipidaemias, Eur Heart J, 37, 2999, 10.1093/eurheartj/ehw272

Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines, Circulation, 129(25 Suppl 2), S1, 10.1161/01.cir.0000437738.63853.7a

Mega, 2015, Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials, Lancet, 385, 2264, 10.1016/S0140-6736(14)61730-X